<DOC>
	<DOCNO>NCT02282215</DOCNO>
	<brief_summary>The purpose study explore safety efficacy CLT-008 extra supportive care measure induction chemotherapy patient acute myeloid leukemia ( AML ) .</brief_summary>
	<brief_title>Safety Efficacy Human Myeloid Progenitor Cells ( CLT-008 ) During Chemotherapy Acute Myeloid Leukemia</brief_title>
	<detailed_description>The prolonged period severe neutropenia cause induction chemotherapy treatment AML associate nearly universal risk febrile neutropenia . Standard supportive care strategy include administration prophylactic anti-bacterial anti-fungal agent , serious breakthrough bacterial fungal infection still occur . Granulocyte colony-stimulating factor ( G-CSF ; filgrastim , Neupogen® ) show shorten duration severe neutropenia , fever , antibiotic use hospitalization follow induction chemotherapy AML . CLT-008 , human allogeneic myeloid progenitor cell product , intend provide cellular target G-CSF produce neutrophils period chemotherapy-induced bone marrow suppression patient 's progenitor cell may limit respond G-CSF . It hypothesize production allogeneic neutrophils CLT-008 sufficient mitigate infection-related consequence induction chemotherapy AML .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Acute myeloid leukemia arise de novo ( per European LeukemiaNet ) 2 . Treated establish chemotherapy regimen base either : 1 . 7+3 : Standarddose cytarabine 100200 mg per meter square continuous infusion 7 day idarubicin 12 mg per meter square daunarubicin 4590 mg per meter square 3 day 2 . Highdose cytarabinebased ( HIDAC ) chemotherapy administer total cytarabine dose ≥ 4 g per meter square alone combination antileukemic agent ( example , anthracyclines , purine nucleoside inhibitor , etoposide , etc . ) 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Screening day chemotherapy initiate 4 . Adequate respiratory function room air oxygen saturation least 92 % 5 . Adequate cardiac function define ejection fraction least 45 % 6 . Serum bilirubin ≤ 1.5 time upper limit normal . Subjects history Gilbert 's syndrome may enrol total bilirubin &lt; 3 mg/dL indirect bilirubin &gt; 1.5 mg/dL 7 . Serum alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 time upper limit normal prior chemotherapy 8 . Serum creatinine ≤ 2 time upper limit normal estimate glomerular filtration rate ≥ 60 mL/min/1.73 meter square per Modification Diet Renal Disease equation ( MDRD ) 9 . All subject , except postmenopausal woman , must willing utilize highly effective method contraception throughout study 10 . Adequately informed nature risk study write informed consent 1 . Pregnant breast feed 2 . Overt central nervous system manifestation leukemia diagnosis 3 . Specifically diagnose uncontrolled fungal , bacterial , viral , infection ( e.g . confirm sepsis , pneumonia , abscess , cellulitis , etc . ) day chemotherapy initiate . `` Uncontrolled '' define exhibit ongoing sign symptom infection without improvement despite antimicrobial treatment . 4 . AML subtype M3 ( promyelocytic leukemia ) 5 . Previous chemotherapy AML 6 . History current human immunodeficiency virus ( HIV ) hepatitis C virus infection 7 . History current clinically significant immunodeficiency 8 . Known contraindication receive GCSF 9 . History current clinically significant alloimmunization leukocyte antigens 10 . Participation another clinical study within 28 day day chemotherapy initiate , study drug device may influence hematopoiesis . Coenrollment another study allow case investigational therapy study version acceptable chemotherapy regimen study per inclusion criterion . 11 . Receiving agent concurrently CLT008 infusion inhibits cell division ( e.g. , methotrexate hydroxyurea ) 12 . Acute chronic medical disorder , opinion investigator medical monitor , may prevent subject complete participation study</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Fever</keyword>
	<keyword>Induction chemotherapy</keyword>
	<keyword>Infection</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Myeloid progenitor cell</keyword>
	<keyword>Neutropenia</keyword>
</DOC>